Phase I, open label, single dose Safety and Pharmacokinetics study of SYM-1219 (Secnidazole) in Healthy Female Volunteers.
Phase of Trial: Phase I
Latest Information Update: 07 Nov 2016
Price : $35 *
At a glance
- Drugs Secnidazole (Primary)
- Indications Bacterial vaginosis
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Symbiomix Therapeutics
- 07 Nov 2016 According to a Symbiomix Therapeutics media release, data will be presented at the 2016 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition.
- 21 Sep 2015 Results presented at the Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy
- 04 Mar 2015 According to a Symbiomix Therapeutics media release, results will be presented at the annual meeting of the American Society of Clinical Pharmacology and Therapeutics.